The goal was to evaluate the activity of two novel heme targeting drugs in Non-Small Cell Lung Cancer models using multi-modality imaging. We found that the novel heme targeting drugs CycT (cyclopamine tartrate) and HSP2 (heme-sequestering peptide 2) were effective in suppressing NSCLC lung tumor growth as assessed by multimodality imaging and confirmed by pathology/histology. MRI detected the H1395 and H1299 orthotopic xenografts and was correlated with PET studies and histology.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords